Hepatitis B Vaccination in Chronic Kidney Disease Patients

Vaccination Schedules

The American Journal of Kidney Diseases recommends a hepatitis B vaccination schedule of 40 μg of Recombivax HB administered at 0, 1, and 6 months or 40 μg of Engerix-B administered at 0, 1, 2, and 6 months for patients with chronic kidney disease (CKD), with post-vaccination antibody testing to ensure adequate protection 1
For pre-dialysis CKD patients, the recommended vaccination schedule is Recombivax HB: 10 μg at 0, 1, and 6 months or Engerix-B: 20 μg IM at 0, 1, and 6 months 2, 3
For dialysis-dependent CKD patients, the recommended vaccination schedule is Recombivax HB: 40 μg at 0, 1, and 6 months or Engerix-B: 40 μg IM at 0, 1, 2, and 6 months 2, 3
For pediatric CKD patients, the recommended vaccination schedule is Recombivax HB: 5 μg at 0, 1, and 6 months or Engerix-B: 10 μg IM at 0, 1, and 6 months 2, 3

The Clinical Infectious Diseases guidelines recommend checking antibody to hepatitis B surface antigen (anti-HBs) titers 1-2 months after completing the primary vaccine series 2, 3
An adequate protective response is defined as anti-HBs ≥10 mIU/mL, according to the American Journal of Kidney Diseases and Clinical Infectious Diseases guidelines 1, 2, 3
For patients who do not respond to the initial series, revaccinate with a complete second series, as recommended by the Clinical Infectious Diseases and American Journal of Kidney Diseases guidelines 1, 2, 3

Alternative vaccination schedules, such as 0, 1, and 4 months or 0, 2, and 4 months, have shown similar seroprotection rates to the standard 0, 1, and 6-month schedule, according to the MMWR Recommendations and Reports 4, 5
Longer intervals between the last two doses result in higher final antibody levels but may increase risk of HBV acquisition in those with delayed response, as reported in the MMWR Recommendations and Reports 4, 5

Using standard adult doses (20 μg) in dialysis patients instead of the recommended higher doses (40 μg) results in inadequate immune response, according to the American Journal of Kidney Diseases 1
Failing to check post-vaccination antibody titers may leave patients unprotected, as recommended by the Clinical Infectious Diseases guidelines 2, 3
Not monitoring antibody levels over time can lead to waning immunity without appropriate booster administration, according to the Clinical Infectious Diseases guidelines 2, 3

The Centers for Disease Control and Prevention recommends measuring anti-HBs titers before vaccination to determine if protection already exists or if revaccination is needed in patients with a history of nephrotic syndrome, with a protective level defined as anti-HBs ≥10 mIU/mL 6
The Centers for Disease Control and Prevention suggests checking anti-HBs titers 1-2 months after completing the vaccination series to assess immune response 6

For patients with impaired renal function, the Infectious Diseases Society of America recommends a higher dose of Recombivax HB 40 μg or Engerix-B 40 μg at 0, 1, and 6 months, with an additional dose of Engerix-B at 2 months for dialysis-dependent patients, due to reduced immune response in kidney disease 7, 8

The Centers for Disease Control and Prevention recommends annual monitoring of anti-HBs titers in patients with a history of nephrotic syndrome 9
The Infectious Diseases Society of America suggests considering alternative strategies such as double-dose vaccination for non-responders after a second series of vaccination 6

The Centers for Disease Control and Prevention recommends that adult hemodialysis patients aged ≥20 years receive a dose of 40 mcg of hepatitis B vaccine administered intramuscularly, not 40 meqs, with a seroconversion rate of 50-67% compared to >95% in healthy adults 10, 11, 12
The American College of Physicians and the Centers for Disease Control and Prevention recommend using a 3-dose series of Recombivax HB at 0, 1, and 6 months or a 4-dose series of Engerix-B at 0, 1, 2, and 6 months for dialysis patients, with a dose of 40 mcg per injection 10, 11, 13

The Centers for Disease Control and Prevention recommends administering hepatitis B vaccine via the intramuscular route for dialysis patients, with a required dose of 40 mcg, as the standard and preferred route, due to significantly impaired immune responses in this population 10, 14

The Centers for Disease Control and Prevention recommends mandatory post-vaccination antibody testing for dialysis patients, with a protective level defined as anti-HBs ≥10 mIU/mL, and annual monitoring due to rapidly declining antibody levels in this population 14, 15

The Centers for Disease Control and Prevention recommends revaccinating patients who fail to achieve anti-HBs ≥10 mIU/mL after the initial series with a complete second series using the same high-dose regimen, with a response rate of 25-50% to an additional vaccine dose and 44-100% to a complete 3-dose revaccination series 14

Patients with chronic kidney disease (CKD) have a substantially increased risk of HBV infection due to frequent blood exposure during dialysis and medical procedures, combined with impaired immune function 16
CKD patients, particularly those on hemodialysis, have significantly higher HBV prevalence than the general population due to repeated vascular access, blood transfusions, and potential nosocomial transmission in dialysis units 17
Once infected, CKD patients face worse outcomes including accelerated liver disease progression and increased mortality 18

The Kidney Disease: Improving Global Outcomes (KDIGO) guidelines recommend immunizing patients with eGFR <30 mL/min/1.73 m² (stages G4-G5) who are at high risk of progression, with response confirmed by serological testing 16

All CKD patients must undergo post-vaccination antibody testing 1-2 months after completing the series to confirm adequate protection (anti-HBs ≥10 mIU/mL) 16
Dialysis patients require annual anti-HBs monitoring, with booster vaccination if levels fall below 10 mIU/mL 16
This differs from immunocompetent individuals who do not need routine boosters 18

Transplant programs should collaborate to vaccinate kidney transplant candidates as early as possible—ideally before dialysis initiation—because serologic response wanes with advancing renal disease. For candidates with compensated cirrhosis due to hepatitis C, pre‑transplant antiviral therapy is advised to permit kidney‑only transplantation; those willing to accept HCV‑positive donor kidneys may postpone antiviral treatment until after transplantation to shorten wait‑list time. 19